Aviva PLC Eagle Pharmaceuticals, Inc. Transaction History

Aviva PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$36.86 - $44.5 $1.05 Million - $1.27 Million	-28,435 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$40.32 - $50.97 $129,427 - $163,613	-3,210 Reduced 10.14%	28,435 $1.19 Million
Q4 2020 Feb 10, 2021	SELL	$41.72 - $51.34 $1.07 Million - $1.32 Million	-25,655 Reduced 44.77%	31,645 $1.47 Million
Q3 2020 Nov 12, 2020	BUY	$37.02 - $51.28 $360,537 - $499,415	9,739 Added 20.48%	57,300 $2.43 Million
Q2 2020 Aug 13, 2020	SELL	$43.24 - $55.02 $1.59 Million - $2.03 Million	-36,882 Reduced 43.68%	47,561 $2.28 Million
Q1 2020 May 14, 2020	BUY	$34.37 - $60.07 $2.9 Million - $5.07 Million	84,443 New	84,443 $3.88 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.